2025年3月，6岁女童小美在上海交通大学医学院附属新华医院接受基因编辑临床试验，旨在治疗罕见遗传病SNIBCPS综合征[1]。治疗后第三天，小美出现发热和严重肾功能损伤，最终因免疫反应于一周内死亡[1]。其父母自筹约86万美元参与该临床试验[1]。
小美的父母随后向学校投诉并要求撤回相关论文[1]。该研究由中国科学院上海生命科学研究院神经科学研究所研究员仇子龙团队完成，于2026年2月发表在《自然》杂志上[1]。上海交通大学医学院于2026年7月26日成立专项工作组对此事进行调查[1]。
A six-year-old girl named Xiaomei died within one week of receiving experimental gene-editing treatment for a rare genetic disorder at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine in March 2025 [1]. The child, who had been diagnosed with Snijders Blok-Campeau syndrome (SNIBCPS)—a condition affecting only 237 known patients globally—developed severe fever and acute kidney dysfunction three days after the procedure and ultimately succumbed to an immune response [1].
Xiaomei's parents invested approximately 860,000 U.S. dollars (about 5.82 million yuan) to participate in the clinical trial led by researcher Qiu Zilong from the Shanghai Institute of Life Sciences under the Chinese Academy of Sciences [1]. Following their daughter's death, the parents filed a complaint with the institution and requested retraction of a related research paper published in Nature in February 2026 [1]. In response, Shanghai Jiao Tong University School of Medicine established a special task force to investigate the incident on July 26, 2026 [1].
